WO2023133053A3 - Methods and compositions for inducing ferroptosis in vivo - Google Patents

Methods and compositions for inducing ferroptosis in vivo Download PDF

Info

Publication number
WO2023133053A3
WO2023133053A3 PCT/US2022/082270 US2022082270W WO2023133053A3 WO 2023133053 A3 WO2023133053 A3 WO 2023133053A3 US 2022082270 W US2022082270 W US 2022082270W WO 2023133053 A3 WO2023133053 A3 WO 2023133053A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
ferroptosis
vivo
compositions
inducing
Prior art date
Application number
PCT/US2022/082270
Other languages
French (fr)
Other versions
WO2023133053A2 (en
Inventor
Vasanthi VISWANATHAN
Jr. John Kittridge Eaton
Original Assignee
Kojin Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kojin Therapeutics, Inc. filed Critical Kojin Therapeutics, Inc.
Publication of WO2023133053A2 publication Critical patent/WO2023133053A2/en
Publication of WO2023133053A3 publication Critical patent/WO2023133053A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

Abstract

Methods and systems for the induction of ferroptosis in a tissue in a subject are provided. Various ferroptosis-inducing agents a described. Various methods of administration are described for optimal ferroptosis induction and killing of target cells.
PCT/US2022/082270 2022-01-07 2022-12-22 Methods and compositions for inducing ferroptosis in vivo WO2023133053A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263297651P 2022-01-07 2022-01-07
US63/297,651 2022-01-07

Publications (2)

Publication Number Publication Date
WO2023133053A2 WO2023133053A2 (en) 2023-07-13
WO2023133053A3 true WO2023133053A3 (en) 2023-09-28

Family

ID=87074112

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/082270 WO2023133053A2 (en) 2022-01-07 2022-12-22 Methods and compositions for inducing ferroptosis in vivo

Country Status (1)

Country Link
WO (1) WO2023133053A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030186248A1 (en) * 2002-03-29 2003-10-02 Erlander Mark G. Interpreting cytological specimens via molecular histological signatures
WO2021119215A1 (en) * 2019-12-09 2021-06-17 President And Fellows Of Harvard College Aldh3a2 inhibition and ferroptosis induction for cancer therapy
WO2021127217A1 (en) * 2019-12-17 2021-06-24 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
WO2021183908A1 (en) * 2020-03-13 2021-09-16 The Trustees Of Columbia University In The City Of New York Gpx4 compounds and compositions and methods of treatment using same
US11541116B1 (en) * 2022-01-07 2023-01-03 Kojin Therapeutics, Inc. Methods and compositions for inducing ferroptosis in vivo

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030186248A1 (en) * 2002-03-29 2003-10-02 Erlander Mark G. Interpreting cytological specimens via molecular histological signatures
WO2021119215A1 (en) * 2019-12-09 2021-06-17 President And Fellows Of Harvard College Aldh3a2 inhibition and ferroptosis induction for cancer therapy
WO2021127217A1 (en) * 2019-12-17 2021-06-24 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
WO2021183908A1 (en) * 2020-03-13 2021-09-16 The Trustees Of Columbia University In The City Of New York Gpx4 compounds and compositions and methods of treatment using same
US11541116B1 (en) * 2022-01-07 2023-01-03 Kojin Therapeutics, Inc. Methods and compositions for inducing ferroptosis in vivo

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RAZMAITĖ VIOLETA, PILECKAS VIDMANTAS, ŠIUKŠČIUS ARTŪRAS, JUŠKIENĖ VIOLETA: "Fatty Acid Composition of Meat and Edible Offal from Free-Living Red Deer (Cervus elaphus)", FOODS, vol. 9, no. 7, 14 July 2020 (2020-07-14), pages 1 - 9, XP093096109, DOI: 10.3390/foods9070923 *

Also Published As

Publication number Publication date
WO2023133053A2 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
WO2002051439A3 (en) Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
BG103806A (en) Controlled release of pharmaceutical preparations in the front eye chamber
WO2003041686A3 (en) Improved therapy for topical diseases
WO2005001080A3 (en) Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
EA200500149A1 (en) Tissue Protective Cytokines for the Protection, Restoration and Stimulation of Reactive Cells, Tissues and Organs
ES2082723B1 (en) PHARMACEUTICAL FORMULATION OF FLUOXETINE IN A DISPERSIBLE FORM.
EA200600076A1 (en) COMPOSITIONS AND METHODS OF INCREASING THE ACTIVITY OF TELOMERASE
IL133253A0 (en) Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
HUP9900886A2 (en) Use of bisphosphonates preventing bone loss associated with immunosuppressive therapy for the preparation of pharmaceutical compositions
WO2021183318A3 (en) Methods and compositions relating to improved combination therapies
MX2022002919A (en) Novel class 2 type ii and type v crispr-cas rna-guided endonucleases.
CA2369739A1 (en) Compositions and methods for improving integrity of compromised body passageways and cavities
BR0010314B1 (en) aqueous solution for tissue and organ preservation.
WO2021211683A3 (en) Compositions and methods for targeted therapeutic delivery to bone
WO2023133053A3 (en) Methods and compositions for inducing ferroptosis in vivo
ITRM970238A0 (en) USE OF THE NERVE GROWTH FACTOR IN THE PRESERVATION OF CORNEAS IN CULTURE, IN THE PRODUCTION OF CORNEAL AND CONJUNCTIVAL TISSUES IN VITRO AND IN THE THERAPY OF CORNEAL AND CONJUNCTIVAL DISEASES
WO2021102474A3 (en) Modular retractor system and method of use
WO1996040168A3 (en) Use of hydroxyethyl starch to prevent post surgical adhesion and as an intracavity carrier device
WO2024030960A3 (en) Compositions and methods for inducing ferroptosis
EP0950416A4 (en) Preventive and/or therapeutic agent for cachexia
WO2023076177A3 (en) Compositions and methods for therapeutic delivery
WO2020209972A3 (en) Effects of age-dependent changes in cell size on endothelial cell growth
WO2023133560A3 (en) Tissue engineering and drug delivery device
WO2004075977A3 (en) Methods using diffuse field ultrasound-induced hyperthermia
MX2023005663A (en) Respiratory treatments.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22919247

Country of ref document: EP

Kind code of ref document: A2